Scarica l'app Stockscreener
1.805
8.71%
0.14
Inmune Bio Inc Borsa (INMB) Ultime notizie
Form 4 INmune Bio Inc For: 7 July By Investing.com - Investing.com Canada
Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
Inmune Bio (INMB) CEO exercises 9,014 April 2024 warrants at $1.40 - Stock Titan
Price to book forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Inmune Bio Inc outlines its immunotherapy focus as shares trade on Nasdaq - AD HOC NEWS
Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - 富途牛牛
Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth? - Sahm
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
INmune Bio Executes Warrant Inducement and Extension Agreement - TipRanks
INMB Seeks Patent Approval for CORDStrom Platform - GuruFocus
INmune Bio files U.S. patent for cell therapy platform - Investing.com
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
INmune Bio files U.S. patent for cell therapy platform By Investing.com - Investing.com Canada
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion - The Manila Times
INmune Bio moves CORDStrom into U.S. patent review - Stock Titan
Price to sales forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM:INMB) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Dynamic Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio, Inc. Actuals & Estimates (NASDAQ:INMB) - TradingView
Inmune Bio total assets 2021-2025 - Statista
INmune Bio receives UK regulatory approval for RDEB treatment plan By Investing.com - Investing.com Australia
INMB Forecast — Price Target — Prediction for 2027 - TradingView
INMB Secures UK Regulatory Approval for Pediatric Treatment Plan - GuruFocus
INmune Bio receives UK regulatory approval for RDEB treatment plan - Investing.com
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ - The Manila Times
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8 - Moomoo
INmune Bio Advances Ebstrocel Toward UK Conditional Approval - TipRanks
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
INMB Receives Regulatory Guidance for CORDStrom in Epidermolysis Bullosa - GuruFocus
INmune Bio receives MHRA alignment for RDEB therapy filing - Investing.com
INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application - marketscreener.com
INmune Bio receives MHRA alignment for RDEB therapy filing By Investing.com - Investing.com India
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB - The Manila Times
INmune Bio wins MHRA backing for 2026 UK rare-disease filing - Stock Titan
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inmune Bio focuses on Alzheimer’s data, shares on NASDAQ in a volatile biotech niche - AD HOC NEWS
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform - BioInformant
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INmune Bio Inc (INMB) Valuation: PE, PB & Fair Value Analysis - TradingKey
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inmune Bio Shareholders Reaffirm Board, Auditor and Incentive Plan - TipRanks
INmune Bio (INMB) holders OK larger stock plan and evergreen share increases - Stock Titan
INMB Q4 2025 Earnings: EPS Surprise of 24.6% Highlights Operational ProgressNon-GAAP Earnings - newsline.com
INMB Q4 2025 Earnings: EPS Beat Surprises Street as Clinical Pipeline AdvancesTax Rate Impact - newsline.com
0.86%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):